90046614 - CAPSIDA BIOTHERAPEUTICS

Information

• Trademark
• 90046614

• Source

• Serial Number

  90046614

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  July 10, 2020
  4 years ago

• Transaction Date

  March 05, 2024
  6 months ago

• Status Date

  March 04, 2024
  6 months ago

• Published for Opposition Date

  February 07, 2023
  a year ago

• Location Date

  April 04, 2023
  a year ago

• Status Code

  731

• Current Location

  INTENT TO USE SECTION

  Employee Name

  LAPTER, ALAIN J

• Attorney Name

  Holly Pranger

  Law Office Assigned Location Code

  L50

• Owners

  • Capsida, Inc.

Case File Statements

• GS0401: Biomanufacturing, namely, manufacturing of pharmaceuticals using biological organisms in the manufacturing process to order and/or specification of others; providing technical information in the field of pharmaceutical manufacturing; custom manufacture of pharmaceuticals; manufacture of nano scale material to the order and specification of others for use in the manufacture of other goods; manufacturing of pharmaceutical preparations for use in gene therapy to the order and specification of others; manufacturing of pharmaceutical preparations for use in gene delivery technology to the order and specification of others; manufacturing of pharmaceutical preparations for use in the treatment of gene therapy treatable diseases to the order and specification of others; manufacturing of pharmaceutical preparations for the treatment of disorders of the central nervous system to the order and specification of others; manufacturing of pharmaceutical preparations for the treatment of cancer to the order and specification of others; manufacture of pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous system and cancer to the order and specification of others; custom manufacturing of biochemical reagents, namely, synthesis for others of clinical medical reagents for use in gene therapy
• GS0051: Pharmaceutical preparations for use in gene therapy; pharmaceutical preparations for use in gene delivery technology for use in the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; pharmaceutical preparations for use in the treatment of gene therapy treatable diseases for use in the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; gene therapy and prophylaxis products, namely, gene transfer, regulation, modulation and delivery pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous system and cancer, in the nature of drug delivery agents consisting of viral capsids that facilitate the delivery of the preparations; pre-filled syringes and vials containing pharmaceutical preparations for the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders and complications associated therewith
• PM0001: CAPSIDA BIO THERAPEUTICS
• GS0011: Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, ribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences; Chemical and biochemical products for use in gene delivery technology namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, ribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences for development of therapeutics and the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders
• GS0441: Medical treatment of genetic diseases and disorders through use of gene therapy; Medical services, in the nature of gene therapy, in the field of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, and urological, diseases and disorders; Providing patient support services relating to the treatment of medical disorders, namely, providing online medical information in the field of pharmaceutical preparations for treatment of various diseases and providing medical consultancy and advisory services, in the field of gene therapy, via a global computer network; Providing health and medical information about medical disorders, namely information pertaining to gene therapy; Information services, namely, providing medical information pertaining to gene therapy to patients; Providing patient support services relating to cancer and cancer treatment in the nature of an internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; Providing information services, namely, providing medical care consultancy and advisory services pertaining to gene therapy via a global computer network in the field of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, and urological, diseases and disorders; Providing medical information services relating to treatment of medical disorders, namely, providing medical information pertaining to gene therapy to patients and families of patients in the field of administering medication, and patient medical information where patients can inquire about medical issues and procedures pertaining to gene therapy from medical personnel; None of the foregoing related to the fields of disease infection control, disease management, or disease risk
• D10000: "BIOTHERAPEUTICS"
• GS0421: Pharmaceutical research and development in the field of gene therapy; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; custom design and development of biochemical reagents, namely for use in the synthesis for others of clinical medical reagents for use in gene therapy; development of pharmaceutical preparations for use in gene therapy and gene delivery technology; development of products being genetic therapies; scientific research in the field of genetic engineering, biotechnology research services, and research and development of new products in the field of gene therapeutics and research tools; research and development in the biotechnology field; scientific and medical research and development in the field of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders and complications associated therewith; scientific research and product development services for others in the pharmaceutical, biotechnology, medical and agriculture fields; testing, inspection, research, or development of pharmaceutical preparations for gene therapy and gene delivery technology; biomedical research and development, scientific research and development, pharmaceutical research and development and product development services in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies, gene delivery technologies, and effectors to regulate, modulate, and characterize disease states; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and product delivery development of biochemical assays; biomedical research and development, scientific research and development, pharmaceutical research and development and product development in the fields of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; medical services, namely, scientific research in the fields of genetic engineering and gene therapy services; medical services, namely, scientific research in the nature of gene therapy design and delivery services in the field of genetic diseases and disorders

Case File Event Statements

• 3/5/2024 - 6 months ago

  44 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 3/4/2024 - 6 months ago

  43 - SOU EXTENSION 2 GRANTED Type: EX2G

• 3/4/2024 - 6 months ago

  42 - SOU EXTENSION 2 FILED Type: EXT2

• 3/4/2024 - 6 months ago

  41 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 9/29/2023 - a year ago

  40 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 9/27/2023 - a year ago

  39 - SOU EXTENSION 1 GRANTED Type: EX1G

• 9/27/2023 - a year ago

  38 - SOU EXTENSION 1 FILED Type: EXT1

• 9/27/2023 - a year ago

  37 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 4/4/2023 - a year ago

  36 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 2/7/2023 - a year ago

  35 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 2/7/2023 - a year ago

  34 - PUBLISHED FOR OPPOSITION Type: PUBO

• 1/18/2023 - a year ago

  33 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 1/5/2023 - a year ago

  32 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 12/21/2022 - a year ago

  31 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 12/21/2022 - a year ago

  30 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 12/21/2022 - a year ago

  29 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 6/23/2022 - 2 years ago

  28 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 6/23/2022 - 2 years ago

  27 - NON-FINAL ACTION E-MAILED Type: GNRT

• 6/23/2022 - 2 years ago

  26 - NON-FINAL ACTION WRITTEN Type: CNRT

• 6/21/2022 - 2 years ago

  25 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK

• 3/16/2022 - 2 years ago

  24 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 3/16/2022 - 2 years ago

  23 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 3/16/2022 - 2 years ago

  22 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR

• 12/1/2021 - 2 years ago

  21 - REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED Type: RCSC

• 6/1/2021 - 3 years ago

  20 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 6/1/2021 - 3 years ago

  19 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 6/1/2021 - 3 years ago

  18 - SUSPENSION LETTER WRITTEN Type: CNSL

• 6/1/2021 - 3 years ago

  17 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 6/1/2021 - 3 years ago

  16 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 6/1/2021 - 3 years ago

  15 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 6/1/2021 - 3 years ago

  14 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 5/28/2021 - 3 years ago

  13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 5/27/2021 - 3 years ago

  12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 5/27/2021 - 3 years ago

  11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 12/4/2020 - 3 years ago

  10 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 12/4/2020 - 3 years ago

  9 - NON-FINAL ACTION E-MAILED Type: GNRT

• 12/4/2020 - 3 years ago

  8 - NON-FINAL ACTION WRITTEN Type: CNRT

• 11/4/2020 - 3 years ago

  7 - AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Type: ASGN

• 10/24/2020 - 3 years ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 10/24/2020 - 3 years ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 10/24/2020 - 3 years ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 10/21/2020 - 3 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 8/6/2020 - 4 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 7/14/2020 - 4 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP